Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years

Simone Dalm, Heying Duan, Andrei Iagaru*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Prostate cancer (PC) remains one of the most prevalent cancer types accounting for 7.3% of all cancer cases in 2020.1 The 5 year survival rate of patients with local or regional disease is greater than 99%, but despite major developments made, the 5 year survival rate of advanced disease remains a mere 35%.2 Accordingly, research is focused on developing novel interventions for early detection and more effective treatment.
Original languageEnglish
Pages (from-to)401-415
Number of pages15
JournalPET Clinics
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 2024

Fingerprint

Dive into the research topics of 'Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years'. Together they form a unique fingerprint.

Cite this